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In recent years, there have been several reviews on gut microbiota,
obesity and cardiometabolism summarizing interventions that
may impact the gut microbiota and have beneﬁcial effects on the
host (some examples include [1e3]). In this review we discuss
how the gut microbiota changes with weight loss (WL) in-
terventions in relation to clinical and dietary parameters. We also
evaluate available evidence on the heterogeneity of response to
these interventions. Two important questions were generated in
this regard: 1) Can response to an intervention be predicted? 2)
Could pre-intervention modiﬁcations to the gut microbiota optimize
WL and metabolic improvement? Finally, we have delineated some
recommendations for future research, such as the importance of
assessment of diet and other environmental exposures in WL
intervention studies, and the need to shift to more integrative
approaches of data analysis.
© 2015 The Authors. Published by Elsevier Ltd on behalf of
European Society for Clinical Nutrition and Metabolism. This is an
open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).lement), patrice.cani@uclouvain.be (P.D. Cani).
r Ltdonbehalfof EuropeanSociety forClinicalNutrition andMetabolism. This is
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1.1. Effect of calorie restriction on gut microbiota e can we predict host responses based on pre-intervention
health status and microbiota composition?
Several studies in animal models and humans have addressed the impact of WL through calorie
restriction (CR) on microbiota composition and its association with clinical outcomes (reviewed in
[1e3]). Some of these studies have analyzed whether certain phenotypes before WL may impact or
predict the effect of the intervention on health outcomes.
1.1.1. Rodent models
Studies in rodentmodels have shed light on the role that gutmicrobiotamay be playing in obesity. It
has been demonstrated in rodents that an obese phenotype can be transmitted via the microbiota. Gut
microbiota, depending on its composition and function, may be involved in several mechanisms
leading to fat mass gain and eventually obesity. Among these mechanisms the role of energy harvest
from food (shown to be more efﬁcient in certain bacterial groups) has been proposed. Germ free mice
are resistant to diet-induced obesity [6,7], but gain weight upon transfer of gut microbiota from
conventionally raisedmice or ob/obmice, potentially through increased capacity for energy harvest [8].
Gut microbiota may also impact host metabolism in the development of rodent obesity through the
induction of hepatic lipogenesis, and suppression of Fiaf in the gut epithelia, leading to upregulation of
LPL activity and increased fat storage [6]. There is also a direct interaction between the gut microbiota,
the gut-associated immune system, and adipose tissue through metabolic endotoxemia [9e11].
Therefore, other effects such as the regulation of lipogenesis and gluconeogenesis, gut hormone
secretion and induction of inﬂammatory response have also been demonstrated in rodents [5]. In
addition, rodent models have been used to investigate the relationship between genetics and gut
microbiota [12], and these studies have shown that different genetic backgrounds can lead to very
diverse hosteenvironment interactions.
Gut microbiota changes due to CR can be signiﬁcant and depend on the type of intervention. For
example, duration of CR can impact both gut microbiota composition and health outcomes. Zhang et al.
showed in mice that lifelong CR led to large and consistent changes in gut microbiota composition [13].
In this study, there was lower midlife serum LPS binding protein (LBP, a surrogate of metabolic
endotoxemia) in mice fed a low fat and calorie diet, as opposed to other dietary compositions. Phyla
that inversely correlated with LBP were positively correlated with lifespan, emphasizing the impor-
tance of low-grade inﬂammation in this context.
1.1.2. In humans
Divergence in human gut microbiota composition is associated to multiple factors. Microbiota
enterotypes have been deﬁned in different populations around the world. Differentiation into these
enterotypes cannot be explained by individual factors such as age or degree of corpulence,
geographical location, or by dietary modiﬁcations of short duration [14]. Instead, long-term dietary
habits and certain clinical characteristics seem to be stronger determinants for these compositional
differences [15].
Obese and non-obese subjects have a different gut microbial proﬁle [16e20]. Ley et al. showed that
obese subjects have lower Bacteroidetes to Firmicutes ratio than lean subjects [8]. However, these
ﬁndings have not been consistent in the literature [21]. Another study showed greater abundance in
the Firmicutes group Eubacterium rectale/Clostridium coccoides in obese women with metabolic syn-
drome versus obese womenwith no metabolic complications and non-obese women [19]. There was a
correlation between this bacterial group and certain clinical outcomes such as visceral adiposity. These
ﬁndings suggest a different energy harvesting potential, consistent with the capacity of Firmicutes
species to degrade non-digestible polysaccharides, although this remains to be proven.
An important aspect of gut microbial composition in relation to host health is microbial richness,
referring to diversity in the gut ecosystem. Microbial richness is overall higher in lean vs. obese sub-
jects, and this correlates with a healthier metabolic proﬁle [16,22]. However even in subjects with
different corpulence (lean vs. obese), metagenomic sequencing has revealed that different patterns of
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certain species such as Faecalibacterium prausnitzii (F. prausnitzii) [16,23,24] and Akkermansia muci-
niphila (A. muciniphila) [25,26] have been repeatedly associated with a healthier status.
In CR studies there have been some consistent shifts in microbial composition. Interestingly, it
appears that certain baseline characteristics in the gut, together with diet, associate with individual
response to CR and lifestyle interventions. Such baseline differences and varied outcomes have been
identiﬁed in the MICRO-Obes study, where a population of 49 overweight and obese individuals has
been thoroughly studied in terms of gut microbiota composition, clinical parameters, and dietary
intake. It was ﬁrst shown that these individuals could be clustered by their response proﬁle to 6 weeks
of CR followed by a 6 week weight stabilization period. There were baseline differences in clinical
parameters and microbiota among the three WL response clusters. Namely, Lactobacillus/Leuconostoc/
Pediococcus group, was most abundant at baseline in the cluster of worst responders to CR and WS.
However, the response to the intervention could be better predicted by baseline insulin sensitivity and
inﬂammatory parameters illustrating the fact that we need deeper insight into the predictive potential
of gut microbiota in dietary interventions [27].
More recently, it was shown in both the MICRO-Obes and MetaHIT studies that individuals can be
stratiﬁed by their microbial richness, and those with higher richness (about 60e80%) tend to have a
healthier metabolic status [16,22] and dietary intake [28]. MICRO-Obes subjects that had higher
baseline microbial richness tended to respond better to the dietary intervention in terms of blood
lipids, insulin sensitivity and low-grade inﬂammation.
Finally, as it will be described in more detail in the following section, higher baseline A. muciniphila
was associated with a healthier metabolic proﬁle in the same study [26]. Individuals with a higher
baseline abundance of this species had better outcomes from the intervention, namely a greater
reduction in waist circumference, blood lipids, and increase in insulin sensitivity. Individuals with
higher A. muciniphila in the context of higher microbial richness were also the most metabolically
healthy throughout the intervention, illustrating the importance to take into account the overall gut
microbial ecosystem, rather than focusing solely on one species.
The functional capacity of the gut microbiota in CR can be studied through modelisation of meta-
genomic information and through direct measure of metabolites in ﬂuids (metabolomics). In a ran-
domized cross-over study comparing a 4-week high protein/low carbohydrate diet to a high protein/
medium carbohydrate regime in obese men, a reduction in abundance of Roseburia spp. and E. rectale,
as well as fecal butyrate, correlated with lower carbohydrate intake [29]. Total fecal short chain fatty
acids (SCFA), acetate, propionate, isovalerate and valerate increased with higher carbohydrate intake.
On the other hand, the high protein/low carbohydrate diet was characterized by a potentially dele-
terious fecal metabolite proﬁle, high in branched chain fatty acids, phenylacetic acid and N-nitroso
compounds [30]. Similarly, another study in obese adults found lower fecal SCFA production in an 8-
week low carbohydrate/high fat regime. This was accompanied by an exacerbation of bowel habits
and a decrease in Biﬁdobacterium [31].
CR interventions in obese adolescents have also demonstrated changes in microbial composition
[32,33]. Interestingly, baseline microbial composition differences were found between good (>4 kg
WL) and bad (<2 kg WL) responders to CR, and changes in certain bacterial groups were associated
with WL or improvement in clinical outcomes (Table 1).
Given the intricate relationship between the gut microbiota and host, a key question is whether
modiﬁcation of gut microbiota before interventions through diet and/or prebiotic treatment (deﬁned later in
this review) has the potential to optimize WL and metabolic improvement. Studying baseline differences
between responders and non-responders is key to answer this question (Fig. 1).
In conclusion, baseline proﬁles in microbiota and metabolic status, together dietary macronutrient
intake, may play a role in outcomes from CR interventions. More detail is needed on the role of
micronutrients. An interaction between diet and microbiota has been identiﬁed in the development of
obesity in human-to-mouse microbial transplantation studies [34,35]. This evidence shows the
importance of analyzing diet in CR interventions. For the most part, intervention periods have lasted
most commonly 1e3 months, with a few exceptions going up to 6 months. Longer follow up periods
should be included in future studies.
Table 1
Overview of CR studies reporting changes in microbiome composition and/or function, along with clinical outcomes and/or dietary intake.
First author Study design Population Method Diet
reported?
Changes in gut
microbiome
Clinical or dietary
outcome associated with
gut microbial changes
Microbiota vs.:
Clinical Metabolites Diet
Ley et al.
(2006)
CR intervention:
two diets (low carb
or low fat) for 1 yr.
12 obese adults 16S rRNA
sequencing
No [
Bacteroidetes:Firmicutes
Increase in Bacteroidetes
abundance correlated
with %WL.
only weight
loss reported
Duncan et al.
(2007)
Randomized cross-
over study: two 4-
wk diets high in
protein with low or
medium carb, with
a 3-day high carb
maintenance diet
before each regime.
19 obese men,
no co-
morbidities
FISH targeting
16S rRNA of 10
dominant
bacterial
groups and
total bacteria
Yes Y carb intake correlated
with Y Roseburia spp/E.
rectale group and
Biﬁdobacteria.
Abundance of other
groups did not change.
 When compared to me-
dium or low carb diets,
SCFA content was
higher in the mainte-
nance diet.
 Butyrate production
was positively corre-
lated with carb intake.
X X
Santacruz
et al. (2009)
CR and exercise
intervention for
10 wks.
36 overweight/
obese
adolescents.
There were low
(WL < 2 kg) and
high
(WL > 4 kg)
responders
16S rRNA qPCR
of 11 bacterial
groups and
total bacteria
Yes Similar abundance of E.
coli, B. longum and B.
adolescentis between
low and high
responders before and
after the intervention.
Differences seen for
other bacterial groups.
Greater change in
bacterial group
abundance for high
responders.
 Bacteroides and Lacto-
bacillus groups were
positively correlated,
and E. coli inversely
correlated, with weight
loss.
 Complex carb intake
was negatively corre-
lated with B. fragilis.
 There was no difference
in dietary intake be-
tween groups.
X X
Nadal et al.
(2009)
CR and exercise
intervention for
10 wks.
39 overweight/
obese
adolescents.
There were low
(WL < 2.5 kg)
and high
(WL > 4 kg)
responders
FISH targeting
16S rRNA of 11
dominant
bacterial
groups and
total bacteria
Yes In high responders: Y C.
histolyticum, E. rectale/
C. coccoides, and C.
lituseburense; [
Bacteroides/Prevotella.
No changes were seen
for low responders.
 Change in C. histo-
lyticum and E. rectale/C.
coccoides were posi-
tively correlated with
WL.
 E. rectale/C. coccoides
correlated with BMI z-
score reduction.
 Changes in fasting
glucose correlated posi-
tively with E. rectale/C.
coccoides and negatively
with Gram-negative
bacteria. Changes in LDL
cholesterol were
inversely correlated
with C. lituseburense.
X Only total
calories
reported
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Brinkworth
et al. (2009)
CR intervention:
low-carb/high-fat
vs. high-carb/low-
fat diet for 8 wks.
91 overweight/
obese adults
Culture system
used for
detection of
Biﬁdobacteria,
Lactobacillus, E.
coli, total
anaerobes and
aerobes
Yes Y Biﬁdobacteria in low
carb/high fat diet group
at 8 wks.
[ Fecal anaerobes in
high carb/low fat diet
group at 8 wks.
 Low carb/high fat group
had more WL than high
carb/low fat group.
 Fecal output and con-
centration of fecal
butyrate, acetate, pro-
pionate, and total SCFA
were lower in the low
carb/high fat diet group.
Only weight
loss reported
X X
Wu et al.
(2011)
Cross-sectional
study (COMBO
study). Subgroup
was part of a 10-
day controlled
feeding study (CAFE
study) (randomized
to high-fat/low-
ﬁber or low-fat/
high-ﬁber).
Normal weight
to obese
subjects with
no chronic co-
morbidities.
COMBO:
N ¼ 98, 2-50y;
CAFE: N ¼ 10,
18-40y
16S rRNA
sequencing,
with a subset of
shotgun
metagenomics.
Rectal biopsy
for CAFE.
Yes Two main enterotypes
identiﬁed: Bacteroides
and Prevotella.
In CAFE, microbiome
composition shifted
after 24 h, but intra-
subject
variation < inter-
individual variation,
and enterotype
classiﬁcation remained
constant.
 Nutrient groups had
opposing correlation
patterns with enter-
otypes: fats vs. plant-
derived nutrients, pro-
teins/amino acids vs.
carbs, and fats vs. carbs.
 A more Western-style
diet proﬁle in Bacter-
oides enterotype. Carb-
rich diet in Prevotella
enterotype.
 Taxa that correlated
with fat-derived nutri-
ents and with calories
were also correlated
with BMI.
 Associations between
nutrients and enter-
otypes were seen for the
FFQ data (habitual diet)
and not for 24h recalls.
 Demographic data
recorded (ethnicity, in-
come, etc) but no asso-
ciations seen with
enterotype.
Only BMI X
Walker et al.
(2011)
CR intervention: 1-
wk maintenance
diet followed by 3-
wk diet high in
resistant starch or
non-starch
polysaccharides
14 overweight
men
16S
rRNA
sequencing,
16S qPCR, and
denaturing
gradient gel
electrophoresis
Yes Microbiota composition
changed rapidly with
diet, but inter-
individual
differences > within-
subject changes.
[ E. rectale, C.
 Starch digestibility was
greatest for non-starch
polysaccharides.
 No emphasis on clinical
data analysis.
X
(continued on next page)
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Table 1 (continued )
First author Study design Population Method Diet
reported?
Changes in gut
microbiome
Clinical or dietary
outcome associated with
gut microbial changes
Microbiota vs.:
Clinical Metabolites Diet
using a cross-over
design. Finally, 3-
wk high-protein CR
diet was consumed.
aerofaciens,and R.
Bromii with resistant
starch diet.
Russell
et al. (2011)
Cross-over study:
1-wk maintenance
diet followed by 4-
wk high protein/
moderate carb or
high protein/low
carb diet.
17 obese men,
no co-
morbidities
FISH for detec-
tion of domi-
nant bacterial
groups and
total bacteria
Yes Y Roseburia/E. rectale
group and Bacteroides
spp. in high protein/low
carb diet.
 Total SCFA were lower
in high protein/low carb
diet.
 Both diets increased
fecal branched-chain
fatty acids, phenylacetic
acid and N-nitroso
compounds, and
decreased butyrate and
ﬁber-derived
antioxidants.
X X X
Kong
et al. (2013)
CR intervention: 6-
wk CR followed by
6wk WS. Diet was
high in protein and
ﬁber, with low gly-
cemic index. Sub-
jects were clustered
into 3 groups ac-
cording to their WL
response.
49 overweight/
obese adults
16S rRNA qPCR
of 7 dominant
bacterial
groups
Yes [ baseline Lactobacillus/
Leuconostoc/Ped-
iococcus group in non-
responders.
 Lactobacillus/Leuconos-
toc/Pediococcus group
abundance correlated to
weight regain during
the WS period, and with
consumption of starch
in the diet.
 Weight regain proﬁles
could not be fully
explained by differences
in clinical parameters or
dietary intake.
X X
Cotillard
et al. (2013)
CR intervention: 6-
wk CR followed by
6wk WS. Diet was
high in protein and
ﬁber, with low
glycemic index.
49 overweight/
obese adults
Shotgun
metagenomic
sequencing
Yes [ microbial richness in
subjects with low
baseline gene richness.
26 out of 39 gene
clusters varied
signiﬁcantly with time;
Y E. rectale and
Biﬁdobacterium spp.
Y several gene clusters
during WS.
 Higher baseline micro-
bial richness correlated
with improved meta-
bolic status after
intervention.
 Change in abundance of
the 26 gene clusters
were correlated with
changes in diet, clinical
outcomes, or both.
X X
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Dao et al.
(2015)
CR intervention: 6-
wk CR followed by
6wk WS. Diet was
high in protein and
ﬁber, with low
glycemic index.
49 overweight/
obese adults
Shotgun
metagenomic
sequencing and
16S rRNA qPCR
of A.
muciniphila
Yes Y A. muciniphila in
subjects with highest
baseline abundance,
but it remained 100
times more abundant
than in subjects with
low baseline
abundance.
There was a core of 26
MGS associated with A.
muciniphila abundance
at least once during the
intervention.
 Higher baseline A.
muciniphila abundance
was associated with a
metabolically healthier
status and with better
outcomes from the di-
etary intervention.
 The most metabolically
healthy subgroup was
characterized by higher
A. muciniphila abun-
dance and microbial
richness.
 Baseline correlation be-
tween A. muciniphila
and serum acetate,
which decreased after
the intervention.
 No correlation between
A. muciniphila and diet,
including diet quality
index.
X X X
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Fig. 1. Comparing responses to weight loss interventions through extensive phenotyping and data integration. There are phenotypic and behavioral traits that differentiate responders vs. non-
responders to weight loss interventions. These differences can be compared 1) at baseline, between responders (status Y) and non-responders (status X) for prediction (yellow proﬁle vs. orange
proﬁle), and 2) before vs. after the intervention (yellow proﬁle vs. blue proﬁle) to study mechanisms that may be involved in a good response to the intervention. Environment may refer to diet,
exercise, behavior, and other environmental exposures. Omics may refer to genomics, epigenomics, transcriptomics, proteomics and metabolomics in different tissues.
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M.C. Dao et al. / Clinical Nutrition Experimental 6 (2016) 39e58 47While these studies have adequately phenotyped the changes in gut microbiota composition with
dietary interventions, it is difﬁcult to go beyond strong correlations and elucidate mechanisms from
these results. As shall be discussed in the last section, data integration approaches allow the simul-
taneous analysis of environment, gut microbiota and host, which may lead to the identiﬁcation of
mechanistic links and therapeutic targets.
1.2. Effects of prebiotic and probiotic on host metabolism: putative links with gut microbes
Numerous studies have demonstrated that manipulating the gut microbiota with dietary inter-
vention (i.e., prebiotics and probiotics) may affect host metabolism (i.e., glucose, lipid and energy
metabolism) (Fig. 2). In this section, we brieﬂy discuss examples showing the impact of such inter-
vention in preclinical models as well as recent evidence suggesting that dietary interventions using pre
and probiotics may also be linked with gut microbes in humans.
Twenty years ago, Gibson and Roberfroid developed the prebiotic concept, recently revised as “A
non digestible compound that, through its metabolization by microorganisms in the gut, modulates
composition and/or activity of the gut microbiota, thus conferring a beneﬁcial physiological effect on the
host” [36]. Over the last decades, this concept has led to the investigation of key questions such as how
do changes in the gut microbiota induced by prebiotics but also speciﬁc bacteria contribute to regulate
energy intake, fat mass development and glucose/lipid metabolism?Wewill ﬁrst discuss data obtained
in rodents and in the second part the effectiveness of such interventions on human health.
1.2.1. Animal models
More than a decade ago, Cani et al. described that the three different prebiotics (i.e. inulin-type
fructans, which varied according to their degree of polymerization (i.e., number of fructose moi-
eties), differentially affected gut peptides secretion. They found that the administration of prebiotic
compounds profoundly changes the gut microbiota composition and metabolic function contributing
to the upregulation of two gut peptides involved in reduced food intake, namely Glucagon-like pep-
tide-1 (GLP-1) and PYY, and decreased plasma levels of the orexigenic peptide, ghrelin [37,38]. By using
culture and non-culture dependent tools it has been shown that the three prebiotics were able to
change the gut microbiota in favor of Biﬁdobacterium spp. The abundance of Biﬁdobacterium spp. was
inversely associated with body weight, fat mass as well as metabolic endotoxemia and inﬂammation
[39]. More recently, thanks to metagenomics tools, novel results have clearly shown that the modu-
lation of the gut microbiota was more complex than a simple change in Biﬁdobacterium spp., indeed,
dozens of taxa were changed upon prebiotic treatment in obese and diabetic rodents [40]. Among the
taxa increased by the treatment, Akkermansia muciniphila was increased by about 100 fold [40].
Interestingly, the abundance of this bacteria was positively associated with a lower fat mass, an
improved glucose tolerance and gut barrier function as well as with the number of intestinal L cells
secreting GLP-1 and PYY [40]. Since this discovery, several studies have shown that the administration
of Akkermansia muciniphila in obese and diabetic rodents reduces fat mass gain, insulin resistance,
metabolic endotoxemia and lowgrade inﬂammation [12,41,42], thereby showing that this bacteriamay
play a crucial role. Although the overall mechanisms are not fully elucidated, this bacterium reinforced
the gut barrier function and contribute to regulate energy homeostasis [41].
Thus, taken together, a variety of rodent model studies indicate that prebiotics may elicit beneﬁcial
impacts inmetabolic disorders associatedwith obesity and diabetes. Moreover, several studies indicate
that some of these effects may be obtained with speciﬁc bacteria often misinterpreted as probiotic.
Notably, the term probiotic is often misused (see the International Scientiﬁc Association for Probiotics
and Prebiotics published a consensus statement clarifying the scope of and appropriate use for the
term ‘probiotic’ (for a review, see [43]).
Besides this important opinion, various strains of Lactobacillus and Biﬁdobacterium have demon-
strated beneﬁcial effects, most of the time by maintaining glucose homeostasis and decreasing
inﬂammation and hepatic steatosis. Importantly, some of these strains also affect body weight and fat
mass development, whereas others do not (for comprehensive reviews on this topic) [44,45].
In summary, abundant literature have reported the impact of speciﬁc Lactobacillus or Biﬁdobacte-
rium strains on obesity and associated disorders in rodents. However, strains are not equally potent in
Fig. 2. Dietary intervention such as prebiotic supplementation as well as gastric surgery impact gut microbiota and host metabolism and thereby represent interesting approaches for the
treatment of obesity and metabolic disorders. Obesity is associated with alterations in metabolism and energy homeostasis. Gastric bypass surgery is associated with changes in gut microbiota
composition and metabolic functions and represents one of the more effective approaches to treat obesity and metabolic disorders. Dietary interventions targeting the gut microbiota, such as
prebiotics, induce changes in gut microbiota composition that are associated with modiﬁcation of the secretion of gut enteroendocrine hormones as well as with a reduction in metabolic
inﬂammation, and glucose, lipid and energy homeostasis dysfunctions.
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M.C. Dao et al. / Clinical Nutrition Experimental 6 (2016) 39e58 49terms of body weight and fat mass loss or improvement of glucose/lipid metabolism and inﬂammatory
markers.
The following examples illustrate the concept that strains are not equipotent. Lactobacillus gasseri
BNR17 reduces body weight and fat mass in overweight rats [46], whereas in diet-induced obese mice,
Lactobacillus plantarum 14 reduces the mean adipocyte size and Lactobacillus paracasei F19 induces a
reduction of total fat mass and plasma triglycerides [47]. Conversely, Lactobacillus acidophilus NCDC
supplementation did not affect body fat mass and/or hepatic steatosis and muscle fat in obese mice
[48]. Lactobacillus casei Shirota reduces insulin resistance and metabolic endotoxemia, without
affecting fat mass and bodyweight in diet-induced obesemice [49]. Finally, L. plantarumWCFS1 did not
change body weight, fat mass or inﬂammation in diet-induced obese mice [41]. These examples clearly
illustrate that although they are all Lactobacillus, speciﬁc strains are efﬁcient on metabolic parameters
whereas others are not.
Similar to the Lactobacillus spp. examples, speciﬁc strains of Biﬁdobacterium have been shown to
targetmetabolic disorders in obese anddiabeticmodels [44]. For example, a recent study has shown that
Biﬁdobacterium pseudocatenulatum CECT 7765 reduces body weight gain, fat mass, plasma glucose and
inﬂammation in diet-induced obese mice [50]. In a similar model, Biﬁdobacterium longum supplemen-
tation has been found to reduce body weight gain, fat mass, insulin resistance, systolic blood pressure,
and metabolic endotoxemia [51]. Another study demonstrated that supplementation with Biﬁdobacte-
rium animalis subsp lactis 420 reduced inﬂammation and improved insulin in obese and diabetic mice
[52]. Again, these selected examples also illustrate that Biﬁdobacterium strains may affect metabolism,
not always by inducing a body weight loss but most likely by improving the intestinal barrier.
1.2.2. In humans
A limited number of studies have evaluated whether effects observed in rodents can similarly be
achieved in humans. Among these studies, the impact of fermentable carbohydrates (including pre-
biotics) feeding on enteroendocrine hormones such as GLP-1, PYYand ghrelin, reduced plasma glucose
and inﬂammatory tone has been generally replicated in both healthy or obese humans [53e55].
However, the impact on fat mass and body weight remain limited [56]. Interestingly, in these studies
the gut microbiota compositionwas not studied, except in Dewulf et al., 2013, who shows that speciﬁc
bacteria are positively and negatively correlated with fat mass, metabolic endotoxemia and glucose/
lipid markers [56].
A study using synbiotic approaches, that is, a supplementationwith prebiotics and probiotic (inulin-
type fructans and Biﬁdobacterium longum) has shown in 66 overweight patients with non-alcoholic
steatohepatitis a reduced steatosis, metabolic endotoxemia, insulin resistance, and inﬂammation
[57]. Excluding these studies using prebiotic supplementation, only few studies have reported a
beneﬁcial impact of probiotics on obesity and type 2 diabetes in humans, with again a certain strain
speciﬁcity (for review [58]). More recently, similar to the results obtained in rodents, it has been shown
that important variations of Akkermansia muciniphila quantity may be observed in the intestine of
obese/overweight subjects. Although, no one knows with precision the level of Akkermansia mucini-
phila required to detect beneﬁcial/healthy versus pathological situation, as discussed earlier in this
review, Dao et al. have recently demonstrated in humans that below a given fecal amount of Akker-
mansia muciniphila obese/overweight subjects were less disposed to respond to the beneﬁcial effect of
a caloric restriction diet in terms of improved cardiometabolic risk factors (i.e., plasma cholesterol,
inﬂammation, insulin resistance and glycemia) [26].
1.3. Bariatric surgery induces substantial shifts in gut microbiota composition
Gut microbiota changes have been thoroughly assessed in bariatric interventions both in animal
models and humans. In general, bariatric surgery leads to a dramatic improvement of pre-surgical
obesity co-morbidities, with some differences observed between the types of bariatric interventions.
The gastric band, for example, leads to a more attenuated WL than sleeve gastrectomy, although they
are both considered restrictive procedures. Roux-en-Y gastric bypass (RYGB) leads to the most
important changes in health outcomes, potentially due to a change in the gut architecture and gut
hormonal secretion, together with extensive WL (Table 2). This particular intervention causes greater
M.C. Dao et al. / Clinical Nutrition Experimental 6 (2016) 39e5850improvements in type 2 diabetes and other obesity co-morbidities [59]. The effect of bariatric surgery
on health has been extensively reviewed in previous publications [60e63].
1.3.1. Rodent models
Studies in mice that have compared different bariatric surgery procedures with non-operated or
sham- operated mice have allowed the deﬁnition of surgery-speciﬁc changes in gut microbiota. Liou
et al. compared mice that had undergone RYGB, non-operated controls weight matched to the RYGB
group, and sham-operated mice fed a HFD ad libitum [64]. Gut microbial composition from Sham and
weight-matched groups was different from that in the RYGB group. Of interest, among other phylo-
genetic changes, there was an increase in abundance of Verrucomicrobia (genus Akkermansia) and
Gammaproteobacteria (genus Escherichia) with RYGB, which correlated with improved metabolic
outcomes. Gut microbiota transfers (i.e. transfer of postsurgery caecal content) to germ-freemice led to
weight improvement. This study showed that microbial changes in RYGB are due to gastrointestinal
reconﬁguration and not just to WL, changes in diet or intestinal transection. The RYGB group had the
highest fecal energy output.
Vertical sleeve gastrectomy (VSG) is becoming popular practice in bariatric interventions. It was
previously believed to be a purely restrictive procedure, but there is now evidence suggesting that
several aspects of digestion, bile acid metabolism and gastrointestinal hormonal secretory proﬁle are
modiﬁed. To this point, it was recently published that circulating bile acids are altered in mice un-
dergoing VSG, which was correlated with shifts in gut microbial composition [65]. Furthermore,
knockout of the bile acid receptor FXR reduced WL and clinical improvement.
A recent study by Tremaroli et al. compared phenotypes in mice receiving fecal transfer from
morbidly obesewomen, orwomen that had undergone either RYGBor vertical banded gastroplasty [66].
One unique feature of this study was that microbiota composition was studied long term, with fecal
samples obtained 9 years after surgery, when the women were weight-stable. Changes in microbiota
were not only maintained over time, they were also surgery-speciﬁc but independent of BMI. Even
though the phenotype was transmitted from the two surgical groups to the mice, there were some
functional and compositional differences inmicrobiota, such as higher Proteobacteria in the RYGB group,
and lower abundance of E. rectale and Roseburia intestinalis in the sleeve group compared to the obese
group. The fecal and circulating metabolite proﬁles were different between groups. This study provides
compelling evidence of the role of microbiota in long term weight maintenance of bariatric patients.
1.3.2. In humans
The potential role of microbiota in human health improvement stemming frombariatric surgery has
been recently summarized [67,68]. As inmouse studies, the composition of gutmicrobiota in humans is
extensively changed with bariatric surgery (Table 2). For example, Furet et al. showed important
changes in microbiota measured with 16S qPCR, after bypass. This included an increase in F. prausnitzii,
which was inversely associated with inﬂammation regardless of diet [17]. Later, Kong et al. published
more detailed gut microbiota information on this group obtained with 16S pyrosequencing [69]. This
analysis showed that microbial richness increased after RYGB, and that approximately half of the
correlations seen between diet and gut microbiota could be explained by dietary intake.
Damms-Machado et al., compared the effect of a very low calorie diet (VLCD) to laparoscopic sleeve
gastrectomy (LSG) over 6 months, with 3 patients per group. They saw a reduction in Firmicutes to
Bacteroidetes ratio, less butyrate fermentation, and more NEFA and bile acid secretion in the LSG group
[70]. The authors argue that the decrease in proportion of Firmicutes would account for the decrease
capacity to ferment SCFA, leading to less calorie extraction from diet and therefore greater beneﬁt from
the intervention. It is difﬁcult to link this to clinical outcomes because the LSG group was heavier at
baseline than the VLCD group.
Other bariatric interventions have included a small number of subjects [71e73]. Their design has
been either cross-sectional, or with short-term follow-up (Table 2). Some changes in gut microbiota
have been consistent, such as a decrease in Firmicutes after surgery, increase Proteobacteria and a
tendency towards an increase in Verrucomicrobia (Akkermansia).
Most importantly, very few bariatric intervention studies assessing microbiota have included di-
etary information and food intake behavior or other kinds of environmental exposures. Our group has
Table 2
Effect of bariatric intervention on gut microbiota composition in humans.
First author Study design Population Method Diet
reported?
Changes in gut
microbiome
Clinical or dietary outcome
associated with gut
microbial changes
Microbiota vs.:
Clinical Metabolites Diet
Damms-
Machado
et al.
(2015)
Comparison of
LSG vs. VLCD, 6-
mo follow up.
10 morbidly
obese women,
but
microbiome
data available
for 6 (3 VLCD, 3
LSG).
Shotgun
metagenomic
sequencing
No Y Bacteroidetes in VLCD
group; Y Firmicutes in LSG
group.
In LSG, Y
Firmicutes:Bacteroidetes,
E. rectale, and [ F.
prausnitzii.
[ Several Firmicutes
species in VLCD.
 The VLCD had an
improvement in blood
lipids while the LSG did
not.
 Metabolic capacity for
butyrate fermentation
was increased for the
VLCD group after the
intervention, but there
was no difference in SCFA
between groups.
 Fecal excretion of NEFA
and bile acids was
increased after LSG.
X X
Zhang et al.
(2009)
Cross-sectional
comparison of
lean, obese and
RYGB patients.
3 lean, 3
morbidly
obese, 3
unrelated BS
patients 8
e15 mo after
surgery.
16S rRNA
sequencing
No Y Firmicutes, [
Gammaproteobacteria in
RYGB.
[ Prevotellaceae (H2
producers) and Archaea
(H2 consumers) in obese.
Verrucomicrobia variable
in normal weight group,
undetectable in obese
group and highest in
RYGB.
None reported.
Furet et al.
(2010)
Bariatric
intervention
(RYGB) with 3
and 6-mo
follow-up, and
comparison to
lean controls.
13 lean and 30
morbidly obese
adults (7 with
T2D)
16S rRNA qPCR
of total bacteria
and 7 select
bacterial
groups
Yes Y F. prausnitzii in obese
diabetic patients.
Y Bacteroides/Prevotella
group in both obese
groups.
After RYGB: [
Bacteroides/Prevotella and
E. coli; Y Biﬁdobacterium
and Lactobacillus/
Leuconostoc/Pediococcus
groups. F. prausnitzii [ at
3 mo and remained stable
at 6 mo.
 F. prausnitzii
inversely related to
inﬂammation indepen-
dently of diet. There was
an inverse correlation
between Leptin decrease
and E. coli increase after
surgery.
 Some of the associations
were observed between
gut microbiota, corpu-
lence and energy intake.
X only total
calories
reported
(continued on next page)
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Table 2 (continued )
First author Study design Population Method Diet
reported?
Changes in gut
microbiome
Clinical or dietary outcome
associated with gut
microbial changes
Microbiota vs.:
Clinical Metabolites Diet
Kong et al.
(2013)
Bariatric
intervention
(RYGB) with 3
and 6-mo
follow-up.
30 morbidly
obese adults (7
with T2D)
16S rRNA
sequencing
Yes Microbial richness 3 mos
post-surgery and then
stabilized.
Microbiome composition
shifted throughout
intervention.
[ Bacteroides, Escherichia,
and Alistipes;Y
Lactobacillus, Dorea,
Blautia,and
Biﬁdobacterium.
 There were more corre-
lations between microbi-
al genera and sAT gene
expression 3 mos after
RYGB.
 Changes in the abun-
dance of 14 discriminant
genera were associated
with changes in clinical
parameters and sAT gene
expression, but most of
these genera were also
associated with calorie
intake.
X only total
calories
reported
Graessler et
al. (2013)
Bariatric
intervention
(RYGB) with 3-
mo follow-up.
6 morbidly
obese adults (5
with T2D). Lean
controls for
microbiome
analysis only.
Shotgun
metagenomic
sequencing
No Microbial composition
shifted after BS, including
changes in 22 microbial
species.
[ obese vs. lean
differences after surgery.
Y Firmicutes and
Bacteroidetes; [
Proteobacteria and
Verrucomicrobia.
Some species level
changes: Y F. prausnitzii
and [ A. mucniphila.
 From PCA analysis, spe-
cies from component 1
(characterized by L. aci-
dophilus) were correlated
to BMI and CRP. Most
correlations observed
between CRP and bacte-
rial species were BMI-
dependent.
 There were 10 species
associated with blood
lipids and 2 with HbA1c
and F. prausnitzii corre-
lated with fasting
glucose.
X
Ward et al.
(2014)
Bariatric
intervention
(RYGB)
measuring
effect of PPI use
on gut
microbiota
before and
6 mo after
RYGB.
8 morbidly
obese adults
16S rRNA
sequencing
No [ Firmicutes Y Bacteroides
pre-surgery in PPI users.
[ Akkermansia
abundance pre-surgery in
PPI users and increased in
both groups.
PPI users tended to have
less excess weight loss than
non-users.
only weight
loss
reported
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M.C. Dao et al. / Clinical Nutrition Experimental 6 (2016) 39e58 53recently reported that dietary quality in bariatric patients is poor, particularly protein intake [74]. In
addition to change in food intake after bariatric surgery, these subjects also receive protein supple-
ments that could impact gut microbiota. Therefore, it will also be important to focus on dietary quality
of bariatric patients before and after surgery to optimize response and increase the likelihood of a shift
to a healthier gut microbiota.
Interpretation of microbial changes with human bariatric interventions needs to be made with
caution and with a thorough knowledge of the clinical background of the patients, as morbidly obese
populations are usually taking multiple medications. The effect of polypharmacy, including metformin
and other diabetes treatments, on the gut microbiota and its relation to health is only now being
elucidated [75,76].
2. Integration of knowledge and potential for future research
Throughout this review we have discussed the interactions between three main elements: the host,
the gut microbiota, and the environment. The advancement of available technologies for the assess-
ment of gut microbiota is key in the work presented here. The ﬁeld is shifting from targeted mea-
surement of speciﬁc bacterial groups to a gut microbiota ecology approach. This is complementary to
the thorough analysis of particular species of interest. With these advances in technology, microbiota
will be more thoroughly characterized and quantiﬁed. This will include RNAseq and more detailed
functional annotations. Other relevant measures include the gut environment, architecture and
ecosystem, in conjunction with functional characteristics of the gut microbiota as a metabolic organ
through the use of metabolomics.
From a clinical point of view, extensive phenotyping of populations is mandatory to identify sub-
groups that may be responding differently to an intervention. Indeed, even if a population seems
uniform in terms of BMI, there is non-negligible heterogeneity in body composition, which in turn
would be associated with different proﬁles of metabolic health, as explained by Ahima and Lazar [77].
Clinical parameters, pathologies and other traits of the host must be studied in detail to identify
subgroups that may respond differently to interventions.
Regarding the environment, there is a wide array of exposures inﬂuencing host and gut microbiota
that are very difﬁcult to measure. Diet is the factor with the greatest potential to inﬂuence the gut
microbiota and, although it is often assessed, it is very difﬁcult tomeasure it reliably. Dietary intake and
habits should be routinely taken into consideration in the kinds of interventions we have covered in
this review. At the same time, there are many other environmental factors that could be inﬂuencing
microbiota, including medication intake, pollution and physical activity.
The gut microbiota is at the interphase between environment and host. It is important to generate
integrated proﬁles from these three elements using data integration and systems biology approaches
[78,79]. This would allow a more profound understanding of the factors that may be inﬂuencing, or
may be inﬂuenced by gut microbiota [80], as well as differentiation of individual subpopulations that
may undergo different responses after a WL intervention (Fig. 1).
2.1. Ecosystem modelisation: a ﬁrst step toward truly personalized nutrition?
An example of a potential approach for personalized improvement in metabolic status can be seen
in the recently published work by Shoaie et al. [81] Given the complexity of the intestinal bacterial
ecosystem characterized by microbeemicrobe interactions, and interactions between microbes, the
environment and the biology of the host, informatics and mathematics experts have used novel ap-
proaches to model these interactions. These modelisation approaches aim at better understanding at
the individual level the interactions between the microbiota ecosystem and dietary intake, and to infer
the potential impact on metabolic health (Fig. 3). As such, knowledge of the individual composition in
gut microbiota leads to the identiﬁcation of metabolites produced in excess or otherwise deﬁcient and
to propose appropriate individualized diet to correct a potential imbalance. Although this approach
may seem a bit theoretical, a ﬁrst step has been taken with the modeling of amino acid exchanges
between different bacterial groups. Dietary protein and amino acids are, in fact, important substrates
for colonic fermentation, where they serve as a nitrogen source for the microbiota. A model called
Fig. 3. Modelisation of the gut ecosystem as a ﬁrst step for personalized nutrition. Individuals with low and high gut microbial richness differ in certain clinical parameters, dietary intake and
metabolite proﬁle. The CASINO toolbox predicts, at the individual level, differences in metabolite production by gut bacteria and proposes changes in dietary intake for individuals with low gene
richness to improve their gut microbiome metabolism. BCAAs, branched chain amino acids.
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M.C. Dao et al. / Clinical Nutrition Experimental 6 (2016) 39e58 55CASINO (Community And Systems-level INteractive Optimization) was applied to analyze these ex-
changes in peoplewith enriched or depletedmicrobiota of theMICRO-Obes study. CASINOwas actually
able to predict differences in production of SCFA and amino acids (such as phenylalanine and branched
chain amino acids) between subjects. Fecal and blood metabolomics analysis allowed validation of the
relevance of this theoretical model. Actually subjects with lower microbial richness had a greater
elevation of amino acids such as phenylalanine and branched chain amino acids (valine, leucine,
isoleucine). Blood elevation of some of these amino acids has been linked to insulin resistance and also
identiﬁed as risk factor for type 2 diabetes (e.g. phenylalanine). The dietary intervention led to a sig-
niﬁcant decrease of these metabolites together with increased gut microbiota richness. CASINO also
modeled which speciﬁc bacterial groups contributed signiﬁcantly to the production of these “delete-
rious” metabolites. Finally, by comparing subjects with low or high gut microbiota richness during the
intervention, the model proposed what speciﬁc dietary changes (i.e. food categories) individuals with
low richness potentially should consume to improve their metabolism.
3. Conclusions
Several studies described a positive impact of CR, bariatric surgery and dietary interventions such as
prebiotic and probiotic supplementation on diet-induced metabolic disorders in rodents and in
humans. Additional studies are warranted to suggest the use of one or another strain as therapeutic
tool in the current clinical practice. It is worth noting that evidence suggests that body weight loss is
not a prerequisite to observe beneﬁcial impact upon health. This implies that changes in gut microbiota
may contribute to the improvement of metabolic disorders via complex mechanisms that can be
indirectly related to energy homeostasis.
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